Overview:Agalimmune was established in 2013. Its shareholders include Loxbridge Research LLP and Animatrix Capital LLP which invest in innovative medical technologies. Agalimmune is located in London, UK and California, USA. Agalimmune has licensed the Alphaject™ immunotherapeutic technology from the University of Massachusetts Medical School, Worcester, MA (USA) where it was researched and developed by a team, led by Professor Uri Galili. The goal of Alphaject™ therapy is to convert the injected tumor into a vaccine that “instructs” the immune system of patients with solid tumors to recognize metastatic tumor cells and destroy them. This treatment may also bring about a long lasting protective anti-tumor immune response.